Baseline type 2 biomarker levels and clinical remission predictors in children with asthma

作者：Mengmeng Chen, Congcong Li, Qiuyan Yang, Huijie Zhang, Yanli Zhang, Na Wang, Jingcheng Dong · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1492644 · 被引用次数：3 · 研究领域：Asthma and respiratory diseases、IL-33, ST2, and ILC Pathways、Inflammation biomarkers and pathways

Background: Few studies have investigated the relationship between baseline type 2 biomarker levels and clinical features in pediatric asthma, particularly in different asthma stages, which may inform prognosis and remission. Objective: To explore the association between baseline Th2 biomarker levels and clinical manifestations in pediatric asthma, identifying predictors of clinical remission. Methods: The study included 172 children with a mean age of 6.87 ± 3.04 years, comprising 119 asthma patients and 53 non-respiratory symptom controls. Clinical evaluations such as lung function tests, FeNO, total IgE, blood eosinophil counts, and skin tests were conducted. Serum biomarkers (TSLP, IL-4/5/13, TARC, Periostin), and IgE were measured by ELISA. Th2-high asthma (IgE >100 IU/mL and eosinophils≥140 cells/μL, n=110) was stratified into acute attack (n=48), persistent asthma (n=26), and clinical remission (n=36). Additionally, mouse models across asthma stages were established to measure TSLP levels in BALF, serum, and lung tissue, to validate its predictor value. Result: Serum TSLP was significantly elevated in acute exacerbation and persistent asthma(P<0.01). Multivariable regression confirmed its independent association with remission (OR=1.009, P=0.023). ROC analysis indicated moderate discriminative capacity of TSLP for remission (AUC=0.59, sensitivity=39.1%, specificity=59.4%). Murine models also showed TSLP levels normalization during remission. Conclusion: Serum TSLP is i...